Abattis Bioceuticals Corp. provided an update as the company moves to a phase of building on recent investments and anticipates significant revenue growth in the fourth quarter of 2018. The Company hopes that these investments will be producing significant revenue streams by the fourth quarter of this year, with such revenues coming from sales of cannabis flower and oils, vaporizers and the roll out of cutting edge new products through Vergence. The Company believes these initiatives will drive growth for the Company through increased market presence and awareness.